Mana.bio

High-Level Overview

Mana.bio is a biotechnology company developing an AI-powered platform for designing and optimizing lipid nanoparticles (LNPs) to enable targeted delivery of oligonucleotide therapies, including RNA-based therapeutics, vaccines, and gene therapies.[1][2][5] It serves biotech and pharmaceutical companies tackling challenges in extra-hepatic RNA delivery, solving key problems like poor tissue specificity, liver accumulation, toxicity, and slow formulation development by accelerating the Design-Build-Test-Learn cycle through machine learning, high-throughput synthesis, and automated testing.[1][4][5][6] The platform has shown growth momentum, including new data presentations at ASGCT in May 2025 demonstrating AI-optimized LNPs for lung, spleen, and other tissues in mouse models, integration of CAS chemical data in 2022, and investment from NFX highlighting its edge in programmable drug delivery.[1][2][6]

Origin Story

Founded in 2021 in Tel Aviv, Israel, Mana.bio emerged from the intersection of AI expertise and nanotechnology to address LNP delivery bottlenecks exposed by mRNA vaccine successes during the COVID-19 pandemic.[1][2][6] Co-founders Yogev Debbi (CEO) and Roy Nevo (CTO) lead the team, supported by scientific advisors Prof. Kira Radinsky (AI/ML expert) and Prof. Avi Schroeder (drug delivery specialist), drawing on domain knowledge in AI, machine learning, nanotechnology, and biotech leadership.[2] The idea crystallized around using AI to predict LNP properties like physiochemical traits, tissue specificity, and safety, starting with novel lipids for non-liver targets; early traction included AI-designed LNPs achieving lung and spleen delivery in mouse models, positioning it as a pioneer in AI-driven LNP platforms.[1][5][6]

Core Differentiators

• AI-Powered Predictive Design: Machine learning models trained on public and proprietary lab data predict LNP attributes (efficacy, safety, tissue targeting) in silico, enabling rapid generation of best-in-class, cell-specific candidates—unlike traditional trial-and-error methods.[1][2][5][6]
• High-Throughput Build-Test Cycle: Automated pipelines synthesize dozens of LNPs weekly and screen them for properties via assays, feeding data back to refine models for continuous improvement.[4][5]
• Extra-Hepatic Targeting Focus: Designs novel lipids that avoid liver accumulation, targeting hard-to-reach organs like lungs and spleen for RNA therapies in cancer, autoimmune, and respiratory diseases—demonstrated in 2025 ASGCT data.[1][6]
• Data Integration and Scalability: Incorporates vast datasets like CAS chemical substances, combining AI with biology and chemistry for programmable, regulatory-familiar delivery platforms.[2][6]

Role in the Broader Tech Landscape

Mana.bio rides the post-COVID RNA therapeutics boom, where mRNA vaccines proved LNP delivery but highlighted limitations in extra-hepatic targeting and speed, amid surging investments and regulatory tailwinds for nucleic acid medicines.[1][6] Timing aligns with generative AI advancements amplifying computational biology, enabling faster iteration than competitors reliant on empirical screening.[6] Market forces like rising demand for gene editing, vaccines, and treatments for rare/undruggable diseases favor its platform, which influences the ecosystem by open-sourcing insights (e.g., ASGCT posters) and partnering with data providers like CAS to standardize AI in biotech R&D.[1][2]

Quick Take & Future Outlook

Mana.bio is poised to lead AI-biotech convergence, with upcoming milestones likely including human trials for AI-optimized LNPs and expanded targeting (e.g., cancer, autoimmune via precision RNA delivery).[1][6] Trends like multimodal AI models and high-throughput automation will accelerate its platform, potentially capturing a slice of the $100B+ RNA market as regulatory paths solidify. Its influence may evolve from startup innovator to ecosystem enabler, licensing designs to Big Pharma—building on its foundational role in unlocking RNA's full potential beyond the liver.[1][5][6]